This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Zenith Capital Corp.
Drug Names(s): RVX 1, RVX-1, ZEN003694, ZEN3694, ZEN 3694
Description: RVX-1 is part of the Resverlogix Epigenitics program, built upon the recent discovery that BET inhibitors may have therapeutic potential in certain human cancers. Recent research has shown that BET inhibition results in the suppression of the activity of the c-myc gene in certain cancer cell types and the resulting loss of c-myc protein leads to inhibition of tumor cell proliferation. Resverlogix has demonstrated that several of their compounds inhibit the proliferation of tumor cells derived from acute myelogenous leukemia (AML) and multiple myeloma (MM) and select solid tumors.
Deal Structure: In April 2013, Resverlogix announced that its Board of Directors has approved a proposal to spin-out its subsidiary, RVX Therapeutics, which will focus on innovative drug research and development by leveraging its epigenetics platform. RVX Therapeutics will exclude Apolipoprotein A-1 (Apo A-1) and RVX-208 technologies, rather focusing on multiple therapeutic indications including autoimmune diseases and cancer (including RVX-1 and RVX-297). The spin-off of Zenith Epigenetics (previously known as RVX Therapeutics) was completed in June 2013.
Additional information available to subscribers only: